Seaport Therapeutics CEO Daphne Zohar (L) and chairman Steve Paul
April 9, 2024 07:19 AM EDTUpdated 09:11 AM
People
Financing
Startups

Up­dat­ed: Steve Paul, Daphne Zo­har re­unite for an­oth­er neu­ro start­up af­ter Karuna suc­cess

Kyle LaHucik

Senior Reporter

That was quick.

One month af­ter Bris­tol My­ers Squibb com­plet­ed its $14 bil­lion ac­qui­si­tion of Karuna Ther­a­peu­tics, the CNS biotech’s ex­ec­u­tive and found­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times